|Member of the U.S. House of Representatives|
from Pennsylvania's 10th district
Assumed office |
January 3, 2011
|Preceded by||Chris Carney|
|United States Attorney for the Middle District of Pennsylvania|
|President||George W. Bush|
|Preceded by||David Barasch|
|Succeeded by||Martin Carlson|
|District Attorney of Lycoming County|
|Preceded by||Brett Feese|
|Succeeded by||Michael Dinges|
Thomas Anthony Marino|
August 13, 1952
Williamsport, Pennsylvania, U.S.
Pennsylvania College of Technology|
Lycoming College (BA)
Dickinson School of Law (JD)
Thomas Anthony Marino (born August 13, 1952) is an American politician and attorney. He is currently serving his fourth term as the U.S. Representative for Pennsylvania's 10th congressional district. He is a member of the Republican Party. Earlier in his career, Marino was the United States Attorney for the United States District Court for the Middle District of Pennsylvania.
On September 1, 2017, President Donald Trump nominated Marino to be Director of the Office of National Drug Control Policy, commonly known as the "drug czar". He withdrew on October 17, 2017 following reports that he had been the chief architect behind a bill that protected pharmaceutical manufacturers and distributors and crippled the DEA's ability to combat the U.S. opioid epidemic.
Early life and education
Marino was born on August 13, 1952 and raised in Lycoming County, Pennsylvania. After graduating from high school, Marino went to work in the factories of central Pennsylvania. At age 30, Marino enrolled in the former Williamsport Area Community College (now Pennsylvania College of Technology). Marino would then transfer to Lycoming College, where he graduated magna cum laude, before completing his J.D. degree at Dickinson School of Law.
After beginning his legal career in private practice, Marino served as a Lycoming County District Attorney from 1992 to 2002. In 2002, Marino was appointed the United States Attorney for the United States District Court for the Middle District of Pennsylvania by President George W. Bush. During his tenure as U.S. Attorney, Marino led the prosecution of executives of Rite Aid for criminal fraud. The company's former president pleaded guilty to conspiring to inflate income by $1.6 billion and conspiring to obstruct justice.
In 2007, Marino resigned from his role as U.S. Attorney for the Middle District of Pennsylvania. In 2007, the new U.S. Attorney for the Middle District of Pennsylvania, Peter Smith, confirmed that neither Marino, nor his office, were ever under review or investigation.
U.S. House of Representatives
Pennsylvania's 10th congressional district, located in central and northeastern Pennsylvania, includes Bradford County, Juniata County, Lycoming County, Mifflin County, Pike County, Snyder County, Sullivan County, Susquehanna County, Union County, Wayne County, and portions of Perry County, Tioga County, Lackawanna County, Monroe County, and Northumberland County.
In 2010, Marino decided to challenge incumbent Democratic U.S. Congressman Chris Carney of Pennsylvania's 10th congressional district. He won the three-candidate Republican primary with 41% of the vote, defeating Dave Madeira (31%) and Snyder County Commissioner Malcolm Derk (28%). On November 2, 2010, Marino defeated Carney 55-45%.
|Democratic||Chris Carney (incumbent)||89,170||45|
In 2012, Marino won re-election to a second term, defeating Democratic nominee Philip Scollo 66%–34%.
|Republican||Tom Marino (incumbent)||179,563||65.6|
In 2014, Marino faced off against Independent Nick Troiano and Democrat Scott Brion. Marino garnered 62% of the vote with Troiano received 13% and Brion received 25%.
|Republican||Tom Marino (incumbent)||112,851||62.6|
- Committee on the Judiciary
- Committee on Foreign Affairs
- Committee on Homeland Security
In July 2013, Marino voted against Justin Amash's amendment #413 to H.R. 2397 "To end authority for the blanket collection of records under the Patriot Act and bar the NSA and other agencies from using Section 215 of the Patriot Act to collect records, including telephone call records, that pertain to persons who are not subject to an investigation under Section 215."
In October 2017, The Washington Post and 60 Minutes reported that Marino was the chief advocate of a 2016 bill that hobbled the ability of the Drug Enforcement Administration to combat the opioid epidemic. Marino introduced the bill, the Ensuring Patient Access and Effective Drug Enforcement Act, in 2014 and again in 2015; it failed both times. The 2014 version was opposed by the DEA and the Justice Department, but the 2015 version was sold as an attempt to "work with the pharmaceutical companies" and was subject to heavy lobbying. A similar version introduced in the Senate by Orrin Hatch passed both houses of Congress by unanimous consent and was signed into law by President Barack Obama on April 19, 2016. The legislation aimed to weaken the DEA's authority to take enforcement action against drug distributors who supplied unscrupulous physician and pharmacists with opioids for diversion to the black market. Previously, the DEA had fined individuals who profited on suspicious sales of painkillers and repeatedly ignored warnings that the painkillers were sold illegally. The new legislation would have made it "virtually impossible" for the DEA to stop these sales, according to internal agency documents, Justice Department documents, and the DEA’s chief administrative law judge. Marino, whose district was heavily affected by the opioid epidemic, declined to comment on the reports.
The drug industry spent at least $106 million lobbying Congress on the legislation between 2014 and 2016. McKesson Corporation, AmerisourceBergen, and Cardinal Health spent $13 million lobbying in support of the bill. When Joseph Rannazzisi, the chief of the Drug Enforcement Administration's Office of Diversion Control, strongly criticized the bill, Marino and his cosponsor Marsha Blackburn demanded that the drug diversion enforcer be investigated by the United States Department of Justice Office of the Inspector General. Nothing came of the investigation but Rannazzisi was removed from his position in August and retired in October 2015.
Office of National Drug Control Policy
In September 2017, President Donald Trump nominated Marino to serve as the Director of the Office of National Drug Control Policy ("drug czar"). In October, Senator Joe Manchin (D-WV) called on Trump to withdraw Marino's nomination. Trump said he would "look into" reports about Marino, putting his nomination in question. On October 17, 2017, Marino withdrew his nomination.
- Straehley, Steve; Wallechinsky, David (September 19, 2017). "Director of the Office of National Drug Control Policy: Who Is Tom Marino?". AllGov. Retrieved 19 September 2017.
- Chappell, Bill (October 17, 2017). "Tom Marino, Trump's Pick As Drug Czar, Withdraws After Damaging Opioid Report". NPR. Retrieved 17 October 2017.
- "Guide to the New Congress" (PDF). CQ Roll Call. 2010-11-04. Archived from the original (PDF) on 2011-07-08. Retrieved 2010-11-24.
- "Marino wants less government, lower taxes". The Daily Item. 2010-10-12. Retrieved 2014-02-04.
- "MARINO, Thomas A., (1952 – )". Biographical Directory of the United States Congress. Retrieved November 6, 2012.
- Scarcella, Francis. "Marino calls accusations 'lies'". Sunbury Daily Item. Retrieved 6 November 2014.
- "PA – District 10 – R Primary Race – May 18, 2010". Our Campaigns. Retrieved 2014-02-04.
- "PA – District 10 Race – Nov 06, 2012". Our Campaigns. Retrieved 2014-02-04.
- "2014 Pennsylvania House Election Results". Politico. Retrieved 2014-11-12.
- "Exclusive: Bradford Commissioner Might Primary Marino". PoliticsPA. 2013-03-05. Retrieved 2014-02-04.
- "Members". House Baltic Caucus. Retrieved 21 February 2018.
- Brady, Chris (2013-03-26). "Marino: Keep guns away from mentally ill, felons". standard-journal.com. Retrieved 2014-02-04.
- "H.Amdt. 413 (Amash) to H.R. 2397: Amendment sought to end authority for the blanket collection of records under the Patriot..." GovTrack.us. 2013-07-24. Retrieved 2014-02-04.
- Bill H.R.3261
- "How Congress allied with drug company lobbyists to derail the DEA's war on opioids". Washington Post. Retrieved 2017-10-16.
- Higham, Scott (October 15, 2017). "The drug industry's triumph over the DEA". Chicago Tribune. Retrieved 18 October 2017.
- Lenny Bernstein; Scott Higham (22 October 2016). "Investigation: The DEA slowed enforcement while the opioid epidemic grew out of control". The Washington Post. Retrieved 17 March 2017.
- "Meet 60 Minutes, Washington Post DEA Whistleblower". CBS News. October 15, 2017. Retrieved 18 October 2017.
- "Too many pills". Reveal, from The Center for Investigative Reporting. Oct 21, 2017.
- "Senator: Trump should withdraw Marino nomination". Citizen's Voice. October 16, 2017. Retrieved 16 October 2017.
- O'Keefe, Ed (October 16, 2017). "Trump promises to 'look into' report on drug czar nominee Marino in wake of Post/'60 Minutes' probe". Washington Post. Retrieved October 16, 2017.
- "Marino for US Congress". Archived from the original on November 30, 2010.
- Congressman Tom Marino official U.S. House site
- Tom Marino for Congress
- Tom Marino at Curlie (based on DMOZ)
- Appearances on C-SPAN
- Biography at the Biographical Directory of the United States Congress
- Profile at Vote Smart
- Financial information (federal office) at the Federal Election Commission
- Legislation sponsored at the Library of Congress
|U.S. House of Representatives|
| Member of the U.S. House of Representatives
from Pennsylvania's 10th congressional district
|Current U.S. order of precedence (ceremonial)|
| United States Representatives by seniority